Affinity Capital Management

ExplORer Surgical Corp. develops an interactive surgical playbook that enhances teamwork and communication in the operating room. Founded in 2013 and based in Chicago, Illinois, the company offers a software solution that allows healthcare providers to compare performance, track case progression in real time, and forecast various operational metrics, such as staffing and equipment use. The platform provides customizable surgical workflows tailored to patient needs and surgeon preferences, minimizing disruptions and reducing waste. By facilitating coordination among surgical teams and offering real-time performance data, the software improves efficiency and quality of care, enabling medical professionals to focus on successful procedures. Additionally, ExplORer Surgical aids medical device companies in the rollout of new devices, contributing to improved medical education and operational cost savings.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Sonitus Medical Inc. is a privately held medical device company based in San Mateo, California, focused on delivering innovative hearing solutions for patients with hearing difficulties. The company is recognized as an emerging leader in bone conduction hearing devices, particularly through its flagship product, the SoundBite Hearing System. This system is notable for being the world's first non-invasive and removable hearing solution, which transmits sound through the teeth, leveraging the principle of bone conduction. The device is FDA cleared as a prosthetic option for treating single-sided deafness and conductive hearing loss. Sonitus Medical aims to expand its technology for future applications, including mixed hearing loss and tinnitus, along with potential consumer and covert communication uses. Founded in June 2006, the company collaborates with otologists, ENTs, and audiologists to enhance the auditory experience for patients.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Baxano, Inc. specializes in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in areas such as the foramen, lateral recess, and central canal, catering to patients with varying degrees of stenosis. Its product line includes the Neuro Check device, which enables surgeons to verify that the device is positioned against the bone with the nerve safely out of the way. Additionally, Baxano provides the MicroBlade Shaver instrument for the removal of impinging bone and ligament, along with essential tools like guidewires, probes, and distal handles. Founded in 2005, Baxano continues to innovate in the field of spinal health.

Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).

Hemosphere developed and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a proprietary graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction.

ValenTx, Inc. is a medical device company based in Maple Grove, Minnesota, established in 2002. It specializes in developing minimally invasive therapy solutions aimed at treating obesity and its related metabolic disorders, including type-2 diabetes and hypertension. One of its key innovations is an endoluminal bypass therapy that replicates the anatomical changes associated with the Roux-en-Y gastric bypass procedure using an adjustable, removable, and replaceable device. ValenTx's focus is on providing effective treatment options for individuals struggling with morbid obesity and related health issues.

CoAxia is a medical device company located in Minneapolis, Minnesota, specializing in solutions for cerebral ischemia. The company develops innovative devices aimed at controlling blood flow, specifically the NeuroFlo and FloControl systems. These devices are designed to redirect blood flow to the brain, thereby helping to reduce the risk of stroke and heart attack in patients experiencing conditions such as vasospasm and heart blockage. Through its research and development efforts, CoAxia focuses on improving treatment outcomes for individuals suffering from these serious medical conditions.

Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).

iScience Interventional specializes in the discovery and development of microcatheter and imaging technologies aimed at enhancing ophthalmic care. The company focuses on a novel approach termed Interventional Ophthalmology, which involves microcatheter-based therapies that allow ophthalmologists to access various anatomical structures within the eye. These technologies facilitate the aspiration of ocular fluids and the delivery of sterile ophthalmic solutions, enabling targeted treatment for a range of ocular diseases. Additionally, iScience Interventional provides medical devices specifically designed for canaloplasty procedures, further contributing to advancements in the management of eye conditions.

Primaeva Medical is a privately held company focused on developing and distributing innovative medical aesthetic devices for dermatologists, plastic surgeons, and other cosmetic practitioners. The company specializes in creating tools aimed at skin tightening and rejuvenation, helping physicians address the signs of aging in their patients. In 2009, Primaeva Medical plans to launch a groundbreaking fractional radiofrequency system designed to provide predictable treatment outcomes for aging skin. By offering advanced technology, Primaeva Medical seeks to enhance the capabilities of aesthetic physicians in restoring youthfulness to their patients.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Spineology Inc. is a medical technology company that specializes in anatomy-conserving solutions for spine surgery. Founded in 1996 and based in Saint Paul, Minnesota, the company offers a range of products including pedicular fixation systems such as Threshold and Fortress, spinal fixation systems like CapLOX II, and biological products including Prime, a liquid tissue matrix, and Armor, an allograft for wound covering. Their portfolio also features interbody fusion systems like Rampart O and Rampart T, as well as instruments for facet fixation, spinous process fixation, and retraction systems such as Medius and SOAR. Additionally, Spineology provides ProMap, an EMG navigation system, and OptiMesh, a graft containment solution. The company’s innovations enable healthcare professionals to perform minimally invasive surgeries, enhancing procedural efficiency and improving patient recovery outcomes.

NovaSys Health is a prominent provider of managed healthcare services, operating one of the largest health plans in Arkansas. With approximately 11,000 contracted providers in the region and over 4,300 in Arkansas, the company emphasizes strong relationships with healthcare providers. It offers a range of health plans and related services, including customized solutions, provider relations, and eligibility and billing administration, catering to a diverse network of hospitals, physicians, and ancillary providers.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

CoAxia is a medical device company located in Minneapolis, Minnesota, specializing in solutions for cerebral ischemia. The company develops innovative devices aimed at controlling blood flow, specifically the NeuroFlo and FloControl systems. These devices are designed to redirect blood flow to the brain, thereby helping to reduce the risk of stroke and heart attack in patients experiencing conditions such as vasospasm and heart blockage. Through its research and development efforts, CoAxia focuses on improving treatment outcomes for individuals suffering from these serious medical conditions.

Atritech is a Minneapolis-based private company founded in 2000, specializing in innovative medical technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, offers a minimally invasive solution for patients with non-valvular atrial fibrillation at risk of stroke by sealing off the left atrial appendage, thereby preventing blood clots from entering the bloodstream. The WATCHMAN Device was first implanted in Germany in 2002 and in the United States in 2003, and has since undergone extensive clinical trials to compare its efficacy against traditional long-term anticoagulation therapies. While the device is CE marked and available in several international markets, it is currently classified for investigational use only within the United States. Atritech's technology aims to enhance the quality of life for patients by providing a permanent alternative to anticoagulant medications.

Pegasus Biologics, Inc. engages in manufacturing, developing, and marketing bioimplants for soft tissue repair and wound care for diabetic ulcers. Its products include OrthADAPT Bioimplant, which is an organized tissue scaffold that used for the repair and reinforcement of soft tissues, such as tendons and ligaments; and Unite Biomatrix, which is an enzyme resistant collagen scaffold that allows for suture retention and intrinsic strength. The company serves orthopedics, sports medicine, neurosurgical, and spine applications. Pegasus Biologics, Inc. was founded in 2003 and is based in Irvine, California. As of July 17, 2009, Pegasus Biologics, Inc. operates as a subsidiary of Synovis Life Technologies Inc.

Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Respicardia, Inc. is focused on enhancing the health of heart failure patients through the development and manufacturing of implantable stimulation therapy solutions. The company's primary product, the remedē System, is an implantable device designed to restore natural breathing patterns during sleep in patients with central sleep apnea. This device utilizes transvenous neurostimulation technology to stimulate the phrenic nerve, thereby improving respiratory rhythm management and overall cardiovascular health. Founded in 2006 and based in Minnetonka, Minnesota, Respicardia aims to improve patient outcomes through innovative therapies that address the critical needs of those suffering from respiratory and cardiovascular diseases. The company has also established a strategic partnership with Sorin Group to further its mission.

CoAxia is a medical device company located in Minneapolis, Minnesota, specializing in solutions for cerebral ischemia. The company develops innovative devices aimed at controlling blood flow, specifically the NeuroFlo and FloControl systems. These devices are designed to redirect blood flow to the brain, thereby helping to reduce the risk of stroke and heart attack in patients experiencing conditions such as vasospasm and heart blockage. Through its research and development efforts, CoAxia focuses on improving treatment outcomes for individuals suffering from these serious medical conditions.

Anulex Technologies focus on developing proprietary medical technology to repair and seal the soft tissue of the spine (anulus) for patients undergoing a surgical procedure to remove a herniated disc (discectomy).

Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Atritech is a Minneapolis-based private company founded in 2000, specializing in innovative medical technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, offers a minimally invasive solution for patients with non-valvular atrial fibrillation at risk of stroke by sealing off the left atrial appendage, thereby preventing blood clots from entering the bloodstream. The WATCHMAN Device was first implanted in Germany in 2002 and in the United States in 2003, and has since undergone extensive clinical trials to compare its efficacy against traditional long-term anticoagulation therapies. While the device is CE marked and available in several international markets, it is currently classified for investigational use only within the United States. Atritech's technology aims to enhance the quality of life for patients by providing a permanent alternative to anticoagulant medications.

Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Myocor is a medical company based in Minnesota that specializes in developing and distributing therapeutic devices aimed at treating mitral valve insufficiency and congestive heart failure. Founded in 1996, Myocor focuses on innovations that enhance cardiac function and improve clinical outcomes for patients with late-stage heart failure. One of its key products, Coapsys, employs a system of pads and a tensioned string inserted through the heart to reshape an enlarged heart and optimize the performance of a leaky mitral valve. Through its technologies, Myocor aims to address the challenges associated with heart failure and provide effective treatment options for affected individuals.

Transneuronix, Inc. is a privately held medical device company focused on the treatment of obesity by stimulation of the stomach with an implantable pacemaker-like device.

Disc Dynamics is a healthcare company. They design and develop medical products. The Company offers surgical alternatives for the treatment of lower back problems and disc diseases. It offers DASCOR Disc arthroplasty system, a catheter-based minimally invasive nucleus replacement technology for the treatment of degenerated lumbar discs. Disc Dynamics was founded by Jeffrey Felt in 2000 and is headquartered in Eden Prairie, Minnesota.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Alliance Medical is a reprocessor of medical devices. The company was founded by Rick Ferreira and is based in Phoenix, Arizona.

Celleration Inc. is a medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, employs low-frequency ultrasound delivered through a saline mist to promote healing by penetrating the wound bed and stimulating cellular activity. Unlike traditional wound treatments, which primarily address the surface, MIST Therapy targets deeper layers to enhance the healing process. Celleration received FDA clearance for this therapy in 2005 and has successfully introduced it to the U.S. market, demonstrating significant clinical and economic benefits across numerous healthcare facilities. To date, over one million MIST Therapy treatments have been administered, positively impacting the lives of more than 65,000 patients. The company operates as a subsidiary of Alliqua BioMedical, Inc.

$25 million in Series C preferred stock financing. The financing will be used to ramp up operations and prepare for sales and marketing in anticipation of the company commercializing its first product, the Novasys Micro-remodeling™ System. The system, which is designed to treat female stress urinary incontinence (SUI), has received the CE Mark for use in the European Union and is pending FDA marketing clearance for sale in the United States. Novasys Medical Inc is testing a new, non-incisional, transurethral treatment which requires no visualization of the treatment site (neither cystoscopy nor fluoroscopy), being guided by familiar balloon palpation (similar to a Foley catheter). In addition, the Novasys Micro-remodeling™ System incorporates numerous, automatic safety features making the treatment process very easy to learn and use. The treatment does not require general anesthesia and is performed in the outpatient or office setting. Not only is the treatment rapid (less than 10 minutes), but patients immediately return to virtually all activities. As there are no incisions, no wound care or dressing changes are required.

Ican Inc., is a provider of Internet-based information and tools for health professionals.

Ican provides Internet-based information and tools for health professionals.

Agiliti specializes in healthcare technology management, offering a range of services designed to support the U.S. healthcare industry. Their offerings include clinical engineering, equipment rental, imaging services, and onsite management, ensuring that healthcare providers have access to essential technology and support. By focusing on the operational needs of healthcare organizations, Agiliti enables these institutions to enhance their efficiency and patient care. Their commitment to providing comprehensive and tailored solutions allows healthcare facilities to effectively manage their technology resources, ultimately leading to better health outcomes.